Kashiv BioSciences, a fully integrated biopharmaceutical company, entered into a senior secured credit agreement with GoldenTree Asset Management as the sole lender. The $150 million credit facility supports Kashiv BioSciences in advancing its world-class infrastructure, enabling the Company to pursue its research, development, and manufacturing strategy in both the U.S. and India. Kashiv is expanding its state-of-the-art manufacturing facilities in Piscataway, New Jersey (8,500L capacity) and Pipan, India (37,000L capacity), dedicated to monoclonal antibody (MAB) drug substance manufacturing. The new facility in Pipan, will be one of India’s largest single-use commercial manufacturing facilities of monoclonal antibodies, serving customers in the U.S., Europe, and rest-of-world markets. The new credit facility will also support working capital requirements, research and development, and other business purposes.

“We are excited to be working with experienced healthcare investors who share our confidence in the Company’s growth,” said Dr. Sandeep Athalye, Global CEO of Kashiv Biosciences. “The favorable structure of this debt facility will allow Kashiv to confidently expand its manufacturing capabilities in India and the U.S. and advance its pipeline of biosimilar candidates. This financing comes at a pivotal time of growth and will allow the Company to have the financial flexibility to execute on our near- and long-term growth objectives.”

J.P. Morgan acted as the structuring agent on the transaction. Milbank LLP served as legal advisor to GoldenTree. K&L Gates served as legal advisor to Kashiv BioSciences.